Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BWV: for fun watch this mystery as hit new lows today 3.51 had high of $90,
and fell hard recently on small dilution.
FNCH: bio boom and bust today 3.65 high, I just started small 2.59 as they have some cash, was $8 this year, with same news, as clinical hold got removed today, and they discontinued over ambitious studies which they are smart to pause and work on main early promise to prove their platform and conserve their cash holdings off 2020 IPO.
FNCH 2.58 trial small buy as platform intact and was $ 8 on same premises ( before the hold up) except they got rid of lesser ambitious programs to conserve their capital which they still maintain.
FNCH 2.61 short lived momo.
ARTW :good looking into as "never wrong" Nelson got my spurs in a fix.
BLTE $14+ as unmet stuff rises.
ARTW: on the 1/2 smile side Iowa just gave them 1/2 mil to position them toward "prosperity".
ACCD 2020 IPO, hit 4.61 this morn, now in mid 5's:
Down 50% today, will lose big customer end of year and always has loses on increased revenue, spends a ton on research and dev.
ACCD down 50% will lose big customer end of year and always has loses on increased revenue, spends a ton on research and dev.
FNCH: like to see massive inside buying as measuring their spins, their need for cash, and their realistically scaling back their initial mega-ambitious goals for their platform, all challenges to discern what current share value should be except betting on short term investor sentiment.
ACCO 7.24 beat earnings but have not read details.
Amazing how cancer research was able to organize precise target areas of discovery without these new tools!
"The goal of the Dependency Map (DepMap) portal is to empower the research community to make discoveries related to cancer vulnerabilities by providing open access to key cancer dependencies analytical and visualization tools."
https://depmap.org/portal/
https://medicalxpress.com/news/2022-04-genetic-achilles-heel-ovarian-uterine.html
Renewable storage systems would be worth trillions but still in its infancy:
https://www.newyorker.com/magazine/2022/04/25/the-renewable-energy-revolution-will-need-renewable-storage
CMPI: little more color:
https://endpts.com/regeneron-buys-art-kriegs-biotech-startup-for-a-discount-price-boosting-i-o-pipeline/
(Hard to reproduce link, as must break up many times and put together.)
CMPI :Apparently oligonucleotides are moving up in supremacy for disease solutions-
Barriers of "Oligos" to be effective:
https://www.nature.com/articles/s41573-020-0075-7
https://en.wikipedia.org/wiki/Oligonucleotide
How many oligonucleotide drugs have been approved?
Currently, 13 oligonucleotide therapeutics have been granted new drug approval (NDA) by the U.S. Food and Drug Administration (FDA) for several different indications (Table 1) [20]. The underlying molecular mechanism is similar for all of these indications: a single gene mutation is responsible for these diseases.Mar 24, 2021
"Oligos"suppier:
https://www.trilinkbiotech.com/custom-rna-oligos?utm_campaign=Oligos&utm_medium=cpc&utm_source=google&gclid=CjwKCAjwu_mSBhAYEiwA5BBmf22SIQwFj8dIoqLvbFHDgNVquyMYQ2pPuCqN_d9igApkSwCCeTlM9RoCSQgQAvD_BwE
https://www.pacelabs.com/life-sciences/cmc-development/oligonucleotides/oligonucleotide-analytical?utm_term=oligo%20custom&utm_campaign=PLS+-+CMC+(Wolfe)&utm_source=adwords&utm_medium=ppc&hsa_acc=2195671737&hsa_cam=1614483538&hsa_grp=60463351665&hsa_ad=513986037741&hsa_src=g&hsa_tgt=kwd-1637447303662&hsa_kw=oligo%20custom&hsa_mt=b&hsa_net=adwords&hsa_ver=3&gclid=CjwKCAjwu_mSBhAYEiwA5BBmfx7YG7qo69K5JYm_SOHXOd1gscVZzIodNzaIy9prFrwXzV5yoMRv5RoC1cgQAvD_BwE
https://www.ixcellsbiotech.com/applications/antisense-oligonucleotide-screening?gclid=CjwKCAjwu_mSBhAYEiwA5BBmfwBYtFJmGupFoyIQJgR565JQyvFHDRL7m4cAB1BoEGVs8vXqdHkLBRoCSMsQAvD_BwE
Even today Oligos point to better RNA delivery solutions
"Other RNA therapies outside of mRNA are being developed or have been approved. Among these are antisense oligonucleotides, which modify gene expression; small interfering RNA (siRNA), which also modifies gene expression via a different mechanism; aptamers, which can bind other ligands, including RNA; and guide RNAs, used for CRISPR targeting. "
Current trends and perspectives in mRNA vaccines | Cytiva (cytivalifesciences.com)
SMDM .1450 on bid!!! Stethoscope out on high resolution: Maybe tit for tat days are over?
CMPI: I read each day new theories about how a new particle "may" revolutionize the progress of overcoming stumbling blocks holding back
effectiveness of previous drug strategies...wonder what data point made it compelling to offer almost 4 times previous share price?
JRSS :China stock "belief force" on their data is................."so we watch".
SMDM .1448 someone just had the news translated.
TRVI matching yearly highs as officer buys millions of shares for unmet cough annoyance.
Irresistible was also the bio field's tendency to hide what it did not know in every "partial" stunning revelation:
https://www.nature.com/articles/d41586-022-00997-5?utm_source=Nature+Briefing&utm_campaign=9d0b1cbbb8-briefing-dy-20220413&utm_medium=email&utm_term=0_c9dfd39373-9d0b1cbbb8-44970129
So a buck ($1) for a real "Buck" in the guts may not be worth a salvage buy?
So how much will cash be distributed this time with EVOL, as CCUR had deep missing cash to minority shareholders?
SMDM: playing dead lately but: "Have gun, will travel"
I am trying to contract with local parlor for 200 pies at current fixed price with payment upfront sort of like pizza options.
GDLLF took my divy today and spent it all on a slice of pizza which they reduced in size by 1/3 and then remarkably went back to old size at same price today @.99 cents, early sign inflation is taking a beating!
6 years ago gave me highest amount of gold bars.
HOOK: also announced earlier mentioned stuff eager to mix with other stuff:
https://ih.advfn.com/stock-market/NASDAQ/hookipa-pharma-HOOK/stock-news/87825950/new-data-show-hookipa-s-arenaviral-immunotherapie
BOSC forgot it was so good then!
Paying billions for a product not yet invented, but slated to be a trillion dollar market:
https://www.theatlantic.com/science/archive/2022/04/big-tech-investment-carbon-removal/629545/
BOSC 2.23 (low float old sqeeze) down almost 1/3 today?
https://ih.advfn.com/stock-market/NASDAQ/bos-better-online-soluti-BOSC/stock-news/87699049/bos-reports-financial-results-for-the-fourth-quart
AUUD 2.19 sold, as do not trust this market.
ISPC 3.83 like this low float with higher yearly revenues near year low's
AUUD 1.96 ok start with low vol. day but expect to buy more near 1.60's with no news.
HOTH up 143% on this PR dropped on investment public eager to see some "novel" cell death occur in a dish for a few days with the word m-RNA in it:
https://ih.advfn.com/stock-market/NASDAQ/hoth-therapeutics-HOTH/stock-news/87803175/hoth-therapeutics-mrna-frame-shifting-therapeutic
Simply put, armed with the "magic signaling box" a metastatic cancer cell whisperer can earn a salary of one trillion dollars.
From your excellent link:
"MRNA technology................................. expands the design space for mRNA beyond therapeutic cancer vaccination. mRNA is now utilized for the most diverse immunotherapeutic approaches, including the equipping of immune cells with antigen receptors and the in vivo production of therapeutic proteins such as antibodies or immunomodulators. mRNA CAR-T cells have the potential to improve the safety profile of CAR-T cell therapy and allow concurrent modification of the lymphocytes by co-delivery of additional mRNAs.
And yet these setbacks:
"..........mRNA vaccine applications have been limited by instability, innate immunogenicity, and inefficient in vivo delivery"
"Despite considerable efforts to develop cancer vaccines, clinical translations of cancer vaccines into efficacious therapies have remained challenging for decades due to highly variate tumor antigens and relevantly low immune response."
https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-021-01335-5
Convinced we need a drug TSAR with funds to plan the efficient process of managing all the stages of discovery necessary to improve the M-RNA technology (potentially one of the most complicated problems conceivable to solve) overseen by independent scientific scholars without ties to any profitable enterprise or politically "glaring" troubling predispositions.
Yet short of picking the right precocious leader, the piece meal process of independent drug discovery will find the necessary solutions but at a rate of failure measured by the seasoned fatalistic expectations of lost lives.
Great explanation.